Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 recruiting2 with results

Enrollment Performance

Analytics

N/A

2(28.6%)

Phase 2

2(28.6%)

Phase 4

2(28.6%)

Phase 1

1(14.3%)

7Total

N/A(2)

Phase 2(2)

Phase 4(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06856902Not ApplicableRecruiting

BEhavioral and Adherence Model for Improving Quality, Health Outcomes and Cost-Effectiveness of healthcaRe

Role: collaborator

NCT03783416Phase 1Recruiting

SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis

Role: collaborator

NCT03648489Phase 2Completed

Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)

Role: collaborator

NCT02843529Not ApplicableCompleted

Evaluation of a Computerized Complex Instrumental Activities of Daily Living Marker (NMI)

Role: collaborator

NCT03106597Phase 4Terminated

Manidipine Versus Amlodipine in Patients With Hypertension

Role: collaborator

NCT03965624Phase 2Withdrawn

Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopenia

Role: collaborator

NCT02246647Completed

Biomarkers for Intestinal Permeability in Patients With Constipation

Role: collaborator

NCT01888237Phase 4Completed

High Dose PPI Triple Therapy Versus Sequential Therapy for Helicobacter Pylori Eradication

Role: collaborator

All 8 trials loaded